<DOC>
	<DOC>NCT01447134</DOC>
	<brief_summary>1. Primary endpoint(s): To determine the relationship between the drug distribution and angiogenesis in head and neck cancer patients. 2. Secondary endpoint(s): To expand the safety database of [F-18]RGD-K5 and to correlate the parameters from the image study to clinical treatment response and prognosis.</brief_summary>
	<brief_title>RGD-K5 in Head and Neck Cancer Patients</brief_title>
	<detailed_description>This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 3 year. Up to 100 patients would be included. Group A would be those to undergo surgical excision or biopsy (n=20); Group B would be those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy (n=40); and Group C would be those with M1 disease to receive biotherapy or chemotherapy (n=40). Group A patients could be included into Group B or C if qualified. Each participant must fulfill all the inclusion and exclusion criteria.</detailed_description>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Head and neck cancer patients (including nasopharyngeal cancer) Age equals or more than 20 years old Referred by Chang Gung Memorial Hospital (CGMH) Head and Neck Oncology team. Willing to sign the informed consent Patient who is pregnant or lactating; Patients with a concomitant or previous 2nd primary cancer other than head and neck malignancy; Unable to tolerate MR or PET/CT scan, such as those with magnetic implants (e.g. those received intracranial aneurysm surgery, cardiac pacemaker, artificial valves replacement, artificial ears), poor blood sugar control (fasting sugar more than 200 mg/dl), claustrophobia, unable to lie still. Unable to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>